Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hoffmann-La Roche |
---|---|
Information provided by: | Hoffmann-La Roche |
ClinicalTrials.gov Identifier: | NCT00420472 |
This study will assess the safety, efficacy and effect on quality of life of switching kidney transplant patients from reduced dose EC-MPS treatment due to gastrointestinal problems to a higher than the equimolar dose of CellCept. Patients will be switched, initially, from EC-MPS (<1440g/day) to an equimolar dose of CellCept, and at the next visit (day 10 +/- 5) the CellCept dose will be increased by 250mg/day, and the daily dose will be split into 3-4 doses. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals.
Condition | Intervention | Phase |
---|---|---|
Kidney Transplantation |
Drug: mycophenolate mofetil [CellCept] |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | An Open-Label Study to Evaluate the Effect on Quality of Life of Switching Kidney Transplant Patients From Reduced Dose EC-MPS to a Higher Than the Equimolar Dose of CellCept |
Study Start Date: | March 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany | |
BERLIN, Germany, 13353 | |
MÜNSTER, Germany, 48149 | |
BERLIN, Germany, 10117 | |
DRESDEN, Germany, 01307 | |
KÖLN, Germany, 51109 | |
ESSEN, Germany, 45122 | |
HANNOVER, Germany, 30625 |
Study Director: | Clinical Trials | Hoffmann-La Roche, +1 973 235 5000 |
Study ID Numbers: | ML20240 |
Study First Received: | January 10, 2007 |
Last Updated: | November 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00420472 |
Health Authority: | Germany: BfArM - Bundesinstitut fur Arzneimittel und Medizinprodukte |
Mycophenolic Acid Mycophenolate mofetil Quality of Life |
Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents Therapeutic Uses Physiological Effects of Drugs |
Enzyme Inhibitors Antibiotics, Antineoplastic Immunosuppressive Agents Pharmacologic Actions |